Tidal Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.07M Buy
21,028
+1,615
+8% +$354K 0.01% 930
2026
Q1
$3.6M Buy
19,413
+13,520
+229% +$2.36M 0.01% 935
2025
Q4
$1M Buy
5,893
+671
+13% +$103K ﹤0.01% 1265
2025
Q3
$688K Sell
5,222
-5,689
-52% -$682K ﹤0.01% 1398
2025
Q2
$1.16M Sell
10,911
-3,010
-22% -$327K 0.01% 971
2025
Q1
$1.73M Sell
13,921
-9,984
-42% -$1.3M 0.01% 755
2024
Q4
$2.94M Buy
23,905
+3,028
+15% +$357K 0.02% 553
2024
Q3
$2.33M Sell
20,877
-792
-4% -$86.8K 0.02% 575
2024
Q2
$2.31M Buy
21,669
+5,014
+30% +$551K 0.03% 498
2024
Q1
$2.01M Buy
16,655
+10,693
+179% +$1.31M 0.03% 526
2023
Q4
$733K Buy
5,962
+264
+5% +$32.9K 0.02% 778
2023
Q3
$738K Sell
5,698
-449
-7% -$59.8K 0.02% 656
2023
Q2
$762K Buy
6,147
+695
+13% +$93.5K 0.02% 628
2023
Q1
$798K Buy
5,452
+2,925
+116% +$433K 0.03% 574
2022
Q4
$403K Buy
2,527
+562
+29% +$82.4K 0.02% 731
2022
Q3
$262K Buy
+1,965
New +$299K 0.01% 822

Other funds holding JAZZ

Tidal Investments's JAZZ Position: Q2 2026 in Review

Tidal Investments increased its Jazz Pharmaceuticals (JAZZ) stake by 8.3% in Q2 2026, buying an estimated $354K and bringing the position to 21,028 shares worth $5.07M. The position accounts for 0.01% of the portfolio, ranked #930.

Tidal Investments first reported a position in JAZZ in Q3 2022 and has held it in 16 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Tidal Investments held 21,028 shares of Jazz Pharmaceuticals worth $5.07M as of Q2 2026.
  • Tidal Investments bought 1,615 Jazz Pharmaceuticals shares in Q2 2026, an estimated $354K.
  • Jazz Pharmaceuticals made up 0.01% of Tidal Investments's portfolio in Q2 2026, its #930 holding.
  • Tidal Investments first reported a position in Jazz Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Tidal Investments's 13F filing for Q2 2026, filed 13 Aug 2026.